Earnings Call · Q4 FY2022·2023-03-01

Q4 22EPS -23.53%·Rev n/aQ3 22EPS +44.95%·Rev n/aQ2 22EPS -56.82%·Rev n/aQ1 22EPS -9.92%·Rev n/a⚠ consensus missing

INOVIO PHARMACEUTICALS, INC. INO

Thomas Hong — Manager of Investor Relations

Jacqueline Shea — President and CEO

Michael Sumner — Chief Medical Officer

Peter Kies — Chief Financial Officer

−1.6%1d on move date−1.2% vs SPY3d+4.8%5d−7.9%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more INO calls or request research access.

More INO calls Browse calls Request research access